IF: 1.578
Cite Score:
1.45
THOMSON REUTERS - SCOPUS

Evaluation of the Effects of Oral N-Acetylcysteine and a Placebo in Paraclinical and Oxidative Stress Parameters of Patients with Chronic Hepatitis B

AUTHORS

Majid Shohrati 1 , Fatemeh Dermanaki 1 , Fatemeh Babaei 1 , Seyed Moayed Alavian 2 , *

AUTHORS INFORMATION

1 Research Center of Chemical Injuries, Baqiyatallah University of Medical Sciences, Tehran, IR.Iran

2 Baqiyatallah Research Center for Gastroenterology and Liver Disease, Alavian@thc.ir, Tehran, IR.Iran

How to Cite: Shohrati M, Dermanaki F, Babaei F, Alavian S. Evaluation of the Effects of Oral N-Acetylcysteine and a Placebo in Paraclinical and Oxidative Stress Parameters of Patients with Chronic Hepatitis B, Hepat Mon. Online ahead of Print ; 10(2):95-100.

ARTICLE INFORMATION

Hepatitis Monthly: 10 (2); 95-100
Article Type: Research Article
Received: September 3, 2009
Accepted: March 20, 2010

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background and Aims: The treatment of chronic hepatitis B (CHB) is a challenging problem today, and previous study has shown that oxidative stress causes the collective pathophysiological conditions of many hepatopathies, so other new therapeutic approaches are needed. Hence, in this study the paraclinical and oxidative stress parameters of the efficacy of N-acetyl cysteine (NAC) as an antioxidant in the treatment of CHB have been evaluated.

Methods: In this double-blind placebo-controlled clinical trial study, 43 patients with CHB were enrolled in 2008 in Tehran, Iran. The patients were randomly assigned to receive either 1200 mg/day NAC or a placebo for 45 days. Paraclinical tests and oxidative stress parameters were measured on experimental day 0 and on day 45.

Results: Liver function tests, i.e. alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) levels were not significantly different in the NAC group and in the placebo group. A reduction in catalase (CAT) activity and an increase in glutathione concentration were statistically significant in the NAC group (P < 0.05).

Conclusions: According to our results, oral NAC is not an effective adjuvant treatment for patients with CHB, but further research with a larger population is needed for the evaluation of the effectiveness of NAC in these patients.

Keywords

Hepatitis B N-Acetylcysteine Oxidative Stress

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: